Literature DB >> 20551469

Targeted treatments in colorectal cancer: state of the art and future perspectives.

Dirk Arnold1, Thomas Seufferlein.   

Abstract

Targeted treatments have generated a lot of hope and hype in the treatment of gastrointestinal tumours. Indeed, the introduction of targeted treatments particularly for colorectal cancer has resulted in substantial improvements in tumour response and progression-free survival of patients. However, it is not fully understood how these agents act in patients, and the preclinical models are not appropriate to predict clinical efficacy. Here the current state of targeted treatments in colorectal cancer is reviewed, focusing on antiepidermal growth factor receptor (EGFR) and antiangiogenic strategies, describing how these agents fit into the therapeutic algorithm of this disease and discussing current understanding of the mechanism of action, biomarkers as well as future therapeutic strategies targeting multiple signalling pathways in colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20551469     DOI: 10.1136/gut.2009.196006

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  20 in total

Review 1.  Targeting the vasculature of visceral tumors: novel insights and treatment perspectives.

Authors:  L V Klotz; M E Eichhorn; B Schwarz; H Seeliger; M K Angele; K-W Jauch; Christiane J Bruns
Journal:  Langenbecks Arch Surg       Date:  2012-03-14       Impact factor: 3.445

2.  Invasion pattern and histologic features of tumor aggressiveness correlate with MMR protein expression, but are independent of activating KRAS and BRAF mutations in CRC.

Authors:  Konrad Steinestel; Jochen K Lennerz; Stefan Eder; Klaus Kraft; Annette Arndt
Journal:  Virchows Arch       Date:  2014-06-12       Impact factor: 4.064

Review 3.  Cancer immunotherapy: Progress and challenges in the clinical setting.

Authors:  Hassane M Zarour; Soldano Ferrone
Journal:  Eur J Immunol       Date:  2011-06       Impact factor: 5.532

4.  The McCAVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC).

Authors:  Johanna C Bendell; Tamara Sauri; Antonio Cubillo Gracián; Rafael Alvarez; Carlos López-López; Pilar García-Alfonso; Maen Hussein; Maria-Luisa Limon Miron; Andrés Cervantes; Clara Montagut; Cristina Santos Vivas; Alberto Bessudo; Patricia Plezia; Veerle Moons; Johannes Andel; Jaafar Bennouna; Andre van der Westhuizen; Leslie Samuel; Simona Rossomanno; Christophe Boetsch; Angelika Lahr; Izolda Franjkovic; Florian Heil; Katharina Lechner; Oliver Krieter; Herbert Hurwitz
Journal:  Oncologist       Date:  2019-09-30

Review 5.  Evolving therapies and FAK inhibitors for the treatment of cancer.

Authors:  Kelli Bullard Dunn; Melissa Heffler; Vita M Golubovskaya
Journal:  Anticancer Agents Med Chem       Date:  2010-12       Impact factor: 2.505

6.  [Abelson interactor 1 (Abi1) in colorectal cancer. From synaptic plasticity to tumor cell migration].

Authors:  K Steinestel; F Gläsle; S Brüderlein; J Steinestel; C Pröpper; P Möller
Journal:  Pathologe       Date:  2013-11       Impact factor: 1.011

7.  Opposite effects of tissue inhibitor of metalloproteinases-1 (TIMP-1) over-expression and knockdown on colorectal liver metastases.

Authors:  Obul R Bandapalli; Eva Paul; Peter Schirmacher; Karsten Brand
Journal:  BMC Res Notes       Date:  2012-01-09

8.  A prospective multicenter phase II study evaluating multimodality treatment of patients with peritoneal carcinomatosis arising from appendiceal and colorectal cancer: the COMBATAC trial.

Authors:  Gabriel Glockzin; Justine Rochon; Dirk Arnold; Sven A Lang; Frank Klebl; Florian Zeman; Michael Koller; Hans J Schlitt; Pompiliu Piso
Journal:  BMC Cancer       Date:  2013-02-07       Impact factor: 4.430

9.  Local targeted therapy of liver metastasis from colon cancer by galactosylated liposome encapsulated with doxorubicin.

Authors:  Chen Zhao; Qiang Feng; Zengpei Dou; Wei Yuan; Chenguang Sui; Xinghua Zhang; Guimin Xia; Hongfang Sun; Jie Ma
Journal:  PLoS One       Date:  2013-09-11       Impact factor: 3.240

10.  Chemotherapy activates cancer-associated fibroblasts to maintain colorectal cancer-initiating cells by IL-17A.

Authors:  Fiorenza Lotti; Awad M Jarrar; Rish K Pai; Masahiro Hitomi; Justin Lathia; Adam Mace; Gerald A Gantt; Kumar Sukhdeo; Jennifer DeVecchio; Amit Vasanji; Patrick Leahy; Anita B Hjelmeland; Matthew F Kalady; Jeremy N Rich
Journal:  J Exp Med       Date:  2013-12-09       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.